S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   171.12 (-1.26%)
MSFT   420.48 (-0.23%)
META   489.93 (-0.80%)
GOOGL   150.72 (-0.10%)
AMZN   180.92 (+0.61%)
TSLA   176.80 (-1.68%)
NVDA   902.50 (+0.00%)
NIO   4.62 (-1.07%)
AMD   182.17 (+1.44%)
BABA   72.39 (+1.12%)
T   17.54 (-0.06%)
F   13.16 (+0.77%)
MU   117.87 (-1.07%)
CGC   9.30 (-2.62%)
GE   176.51 (-2.00%)
DIS   122.99 (+1.66%)
AMC   3.82 (-11.98%)
PFE   27.82 (+0.14%)
PYPL   66.68 (+0.17%)
XOM   115.21 (+0.21%)
NASDAQ:ANGO

AngioDynamics (ANGO) Stock Price, News & Analysis

$5.85
+0.15 (+2.63%)
(As of 10:27 AM ET)
Today's Range
$5.73
$5.87
50-Day Range
$5.27
$6.22
52-Week Range
$5.26
$12.62
Volume
52,847 shs
Average Volume
502,080 shs
Market Capitalization
$233.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

AngioDynamics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
156.4% Upside
$15.00 Price Target
Short Interest
Bearish
6.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
-0.04mentions of AngioDynamics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.44) to ($0.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.03 out of 5 stars

Medical Sector

232nd out of 939 stocks

Surgical & Medical Instruments Industry

26th out of 98 stocks

ANGO stock logo

About AngioDynamics Stock (NASDAQ:ANGO)

AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

ANGO Stock Price History

ANGO Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
ELV Feb 2024 410.000 put
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
AngioDynamics Receives FDA 510(k) Clearance For Auryon XL Catheter
AngioDynamics, Inc. (ANGO)
Oppenheimer Keeps Their Hold Rating on AngioDynamics (ANGO)
See More Headlines
Receive ANGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
1/05/2024
Today
3/28/2024
Next Earnings (Confirmed)
4/04/2024
Fiscal Year End
5/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ANGO
CUSIP
03475V10
Employees
815
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$18.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+156.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-52,440,000.00
Pretax Margin
-2.82%

Debt

Sales & Book Value

Annual Sales
$338.75 million
Cash Flow
$1.19 per share
Book Value
$9.64 per share

Miscellaneous

Free Float
37,822,000
Market Cap
$233.12 million
Optionable
Optionable
Beta
0.66

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

ANGO Stock Analysis - Frequently Asked Questions

Should I buy or sell AngioDynamics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANGO shares.
View ANGO analyst ratings
or view top-rated stocks.

What is AngioDynamics' stock price target for 2024?

3 brokers have issued twelve-month target prices for AngioDynamics' stock. Their ANGO share price targets range from $10.00 to $18.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 156.4% from the stock's current price.
View analysts price targets for ANGO
or view top-rated stocks among Wall Street analysts.

How have ANGO shares performed in 2024?

AngioDynamics' stock was trading at $7.84 at the beginning of the year. Since then, ANGO shares have decreased by 25.4% and is now trading at $5.85.
View the best growth stocks for 2024 here
.

Are investors shorting AngioDynamics?

AngioDynamics saw a increase in short interest in March. As of March 15th, there was short interest totaling 2,460,000 shares, an increase of 7.0% from the February 29th total of 2,300,000 shares. Based on an average daily trading volume, of 502,000 shares, the days-to-cover ratio is presently 4.9 days.
View AngioDynamics' Short Interest
.

When is AngioDynamics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our ANGO earnings forecast
.

How can I listen to AngioDynamics' earnings call?

AngioDynamics will be holding an earnings conference call on Thursday, April 4th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-6671 with passcode "13745239".

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) posted its quarterly earnings results on Friday, January, 5th. The medical instruments supplier reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04. The medical instruments supplier had revenue of $79.07 million for the quarter, compared to the consensus estimate of $81.65 million. AngioDynamics had a negative net margin of 4.28% and a negative trailing twelve-month return on equity of 1.78%.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics updated its FY 2024 earnings guidance on Friday, January, 5th. The company provided EPS guidance of -0.420--0.350 for the period, compared to the consensus earnings per share estimate of -0.320. The company issued revenue guidance of $320.0 million-$325.0 million, compared to the consensus revenue estimate of $329.1 million.

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.69%), Vanguard Group Inc. (5.69%), Dimensional Fund Advisors LP (3.74%), Armistice Capital LLC (2.01%), Fund 1 Investments LLC (1.25%) and Nuveen Asset Management LLC (1.08%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends
.

How do I buy shares of AngioDynamics?

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AngioDynamics have any subsidiaries?
The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.
Read More
This page (NASDAQ:ANGO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners